Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
233.50
+4.51 (1.97%)
At close: Feb 27, 2026, 4:00 PM EST
243.00
+9.50 (4.07%)
After-hours: Feb 27, 2026, 7:55 PM EST
Ascendis Pharma Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Ascendis Pharma stock have an average target of 277.13, with a low estimate of 250 and a high estimate of 342. The average target predicts an increase of 18.69% from the current stock price of 233.50.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ascendis Pharma stock from 15 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 6 | 6 | 6 | 5 |
| Buy | 10 | 10 | 9 | 9 | 10 | 10 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 17 | 15 | 15 | 16 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $246 → $262 | Buy | Maintains | $246 → $262 | +12.21% | Feb 12, 2026 |
| Wedbush | Wedbush | Buy Maintains $240 → $273 | Buy | Maintains | $240 → $273 | +16.92% | Feb 12, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $246 → $260 | Strong Buy | Maintains | $246 → $260 | +11.35% | Jan 30, 2026 |
| Barclays | Barclays | Buy Initiates $342 | Buy | Initiates | $342 | +46.47% | Jan 28, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $245 → $250 | Buy | Maintains | $245 → $250 | +7.07% | Jan 20, 2026 |
Financial Forecast
Revenue This Year
1.43B
from 720.13M
Increased by 98.99%
Revenue Next Year
2.03B
from 1.43B
Increased by 41.45%
EPS This Year
3.76
from -3.76
EPS Next Year
9.91
from 3.76
Increased by 163.81%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.6B | 2.5B | |||
| Avg | 1.4B | 2.0B | |||
| Low | 1.2B | 1.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 122.6% | 73.6% | |||
| Avg | 99.0% | 41.5% | |||
| Low | 62.7% | 6.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 7.16 | 19.98 | |||
| Avg | 3.76 | 9.91 | |||
| Low | 1.22 | 3.33 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 432.0% | |||
| Avg | - | 163.8% | |||
| Low | - | -11.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.